Core Viewpoint - GRI Bio, Inc. is advancing its innovative pipeline of Natural Killer T (NKT) cell modulators, with a focus on treating inflammatory, fibrotic, and autoimmune diseases, and has received a notice of intent to grant a European patent for a key compound [3][4]. Group 1: Patent Developments - The European Patent Office has issued a decision to grant a patent for application number 19,166,502, which pertains to oxygenated amino or ammonium-containing sulfonic acid, phosphonic acid, and carboxylic acid derivatives [3]. - The company anticipates the official issuance of the patent on January 16, 2025, which will enhance its intellectual property portfolio [3][4]. Group 2: Clinical Programs - GRI Bio is currently advancing its lead program, GRI-0621, in a Phase 2a clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), with interim data expected in Q1 2025 and topline results in Q2 2025 [1]. - The company is also developing GRI-0803, a novel activator of human type 2 NKT cells, aimed at treating systemic lupus erythematosus (SLE), with promising preclinical results indicating inhibition of lupus nephritis and improved survival rates [7][8]. Group 3: Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on changing the treatment landscape for inflammatory, fibrotic, and autoimmune diseases by targeting NKT cells to restore immune system balance [8]. - The company has a library of over 500 proprietary compounds, which supports its growing pipeline of therapies [4][8].
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds